Cardiovascular disease remains the leading cause of death in patients with diabetes.
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective antidiabetic
therapies in patients with type 2 diabetes mellitus and are associated with improved …

Diabetes Mellitus (DM) is a multi-factorial chronic health condition that affects a large part of
population and according to the World Health Organization (WHO) the number of adults …

Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of
morbidity and mortality in patients with established disease. Secular trends in the …

Background: Sodium glucose cotransporter 2 inhibitors (SGLT2 inhibitors) prevent heart
failure (HF) hospitalizations in patients with type 2 diabetes and improve outcomes in those …

Background: Outcome trials in patients with type 2 diabetes mellitus have demonstrated
reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 …

Several yeasts, which are eukaryotic microorganisms, have long been used in different
industries due to their potential applications, both for fermentation and for the production of …

Cardiovascular disease remains the principal cause of death and disability among patients
with diabetes mellitus. Diabetes mellitus exacerbates mechanisms underlying …

Background The effects of empagliflozin, an inhibitor of sodium–glucose cotransporter 2, in
addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 …

The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%),
hospitalization for heart failure (35%), and death from any cause (32%) observed in the …